On September 10, Moderna, Inc. fell 3.38% in regular trading, trading at 135.77 USD/share, with turnover of 1.018 billion USD, marking a second consecutive session of weakness.

The broader biotechnology sector continued to trade under pressure, with Amgen down 0.28% and Gilead Sciences down 0.71%, reflecting sustained industry-wide selling. Moderna had previously surged sharply following positive Phase 3 data for its individualized mRNA cancer vaccine developed in collaboration with Merck, but the stock has since entered a pullback phase as the market digests the prior rally.

On the institutional front, Rothschild & Co Redburn recently downgraded Moderna to Sell from Neutral, while UBS maintained a Neutral rating with a 150 USD price target, noting three upcoming individualized neoantigen therapy data readouts as potential catalysts. Meanwhile, the average analyst rating remains at Hold with a mean price target of 108 USD, suggesting limited near-term upside consensus. The ongoing correction reflects a broader repricing of the stock following its rapid ascent, as investors reassess the pace of clinical progress and commercial potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)